Veru Inc. (VERU)
After hours:
| Previous Close | 1.3500 |
| Open | 1.3800 |
| Bid | 1.4600 x 2500 |
| Ask | 1.4900 x 1900 |
| Day's Range | 1.3500 - 1.4900 |
| 52 Week Range | 0.3600 - 1.9200 |
| Volume | |
| Avg. Volume | 2,547,932 |
| Market Cap | 218.108M |
| Beta (5Y Monthly) | -0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 28, 2014 |
| 1y Target Est | 2.75 |
GlobeNewswireVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update. The audio webcast wi
ZacksVeru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
- GlobeNewswire
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has enrolled the first pati
